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TERAPI PENGHANTARAN SEL TUNJANG MESENKIMA DARIPADA TISU 
LEMAK MANUSIA YANG MENGEKSPRESKAN ANGIOPOIETIN-1 DALAM 
MODEL UJIKAJI KERADANGAN PADA SALUR PERNAFASAN 
 
ABSTRAK 
Terapi berasaskan sel tunjang mesenkima (MSCs) didapati mampu membantu 
mempercepatkan proses pemulihan dalaman dengan meningkatkan kapasiti regeneratif paru-
paru yang terhad akibat penyakit paru-paru kronik serta akibat kecederaan. Walau 
bagaimanapun, mekanisme tindakan MSCs dalam membantu proses regenerasi serta 
pemulihan salur pernafasan pada peringkat sel dan molekul adalah masih tidak jelas. Kajian 
ini bertujuan untuk menyiasat kesan penghantaran sel MSCs yang dipencilkan daripada tisu 
lemak manusia (hAD-MSCs) serta menilai kesan selanjutnya yang melibatkan kombinasi 
antara MSCs dan gen ANGPT1 (MSC-pANGPT1) dalam model keradangan salur 
pernafasan pada arnab menggunakan teknik penghantaran secara aerosol. Gen ANGPT1 
memiliki sifat anti-keradangan, anti-ketelapan serta pelindung kepada sel endotelial. Oleh 
yang demikian, gabungan bersama antara MSCs dan ANGPT1 berpotensi dalam merawat 
keradangan pada salur pernafasan. Transfeksi hAD-MSCs dengan gen ANGPT1 dilakukan 
dengan menggunakan teknik mikroporasi. Dalam kajian haiwan, arnab pada awalnya 
disensitifkan dengan suntikan gabungan ovalbumin (Ova) dan alum, dan diikuti dengan 
sedutan Ova. Tindakan ini adalah untuk mencetuskan keradangan pada salur pernafasan 
yang mempunyai ciri-ciri yang dikaitkan dengan penyakit asma. MSCs dan MSC-pANGPT1 
telah dihantar ke dalam salur pernafasan arnab yang tercedera melalui peranti 
MicroSprayer® Aerosolizer 48 jam selepas kecederaan. Penilaian histopatologi keradangan 
pada salur pernafasan serta tindakbalas keradangan tempatan telah diukur secara kuantitatif 
pada hari ketiga selepas penghantaran sel. Untuk menyiasat kesan fungsi MSCs terhadap 
regenerasi dan pemulihan pada salur pernafasan, satu model kultur bersama in vitro tidak 
langsung telah dibangunkan. Tisu salur pernafasan yang telah tercedera telah dikulturkan 
xvi 
 
bersama atau tanpa MSCs. Pendekatan proteomik telah digunakan untuk mengenalpasti 
protein yang dirembeskan oleh MSCs hasil tindakbalas kepada epitelium salur pernafasan 
yang tercedera akibat induksi oleh Ova. Strategi ini adalah untuk mengenalpasti faktor-faktor 
yang dirembeskan oleh MSCs dimana ianya memainkan peranan penting dalam proses 
regenerasi dan pemulihan epitelium. Analisis spektrometri massa kromatografi-tandem 
dilakukan untuk menganalisis faktor-faktor yang dirembeskan oleh MSCs dan 
penglibatannya dalam proses regenerasi dan pemulihan epitelium telah dinilai menggunakan 
kaedah histologi. Kajian ini membuktikan bahawa teknik mikroporasi merupakan teknik 
yang hebat berbanding teknik lain dalam kemampuannya untuk transfek hAD-MSCs tanpa 
mengganggu proses proliferasi dan pembezaan sel hAD-MSCs.  Penghantaran MSCs dan 
MSC-pANGPT1melalui kaedah aerosol mampu mengakibatkan pengurangan yang ketara 
pada keradangan salur pernafasan, seperti yang dapat dilihat oleh penyusutan ketebalan 
dinding salur pernafasan dan pengurangan penyusupan sel-sel granulosit pada bahagian 
sekitar bronkiol dan salur darah. Terapi oleh kedua-dua sel ini, MSCs dan MSC-pANGPT1 
dilihat mampu mengurangkan penyusupan sel-sel yang terlibat dalam keradangan pada salur 
pernafasan serta dalam cecair “bronchoalveolar lavage” (BAL) dan hiperplasia sel-sel goblet. 
Manakala, penghantaran MSC-pANGPT1 melalui aerosol memberi impak tambahan dengan 
mengurangkan kadar ekspresi pelbagai gen pro-keradangan kepada kadar normal. Penilaian 
histologi kultur in vitro bersama membuktikan bahawa sifat stimulasi MSCs berupaya 
meningkatan kebolehan sel-sel epitelium pernafasan (AECs) bermigrasi, berproliferasi serta 
melakukan pembezaan bagi memulihkan kecederaan epitelium pada salur pernafasan. 
Sebatian yang dirembeskan oleh MSCs juga menunjukkan proses peralihan epitelium kepada 
mesenkima (EMT) sebagai proses awal pembaikan epitelium salur pernafasan. 
Pengenalpastian 54 protein yang dirembeskan oleh MSC yang mana kira-kira 43 
daripadanya didapati terlibat dalam proses mempercepatkan regenerasi serta pemulihan 
epitelium pada salur pernafasan. Protein-protein yang dirembeskan ini merangsang 
kebolehan mekanisme pemulihan dalaman bermigrasi, berproliferasi dan melaksanakan 
pembezaan. Di samping itu, protein-protein ini juga mencetus proses awal pemulihan iaitu 
xvii 
 
peralihan epitelium-mesenkima (EMT). Kajian ini memberikan pemahaman tentang terapi 
berasaskan MSC pada peringkat sel dan molekul sebagai asas untuk terapi bagi rawatan 
kecederaan paru-paru pada masa hadapan. 
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CELL-BASED THERAPY OF HUMAN ADIPOSE-DERIVED MESENCHYMAL 
STEM CELL EXPRESSING ANGIOPOIETIN-1 IN AN EXPERIMENTAL MODEL 
OF AIRWAY INFLAMMATION 
 
ABSTRACT 
Cell-based therapy of mesenchymal stem cells (MSCs) has been shown to enhance 
the endogenous repair process by increasing the limited regenerative capacity of the lung in 
chronic lung disorders as well as following injury. However, the underlying cellular and 
molecular mechanisms of MSCs to enhance airway regeneration and repair are remain 
unclear. This study was aimed to investigate the effect of delivering human adipose-derived 
MSCs (hAD-MSCs) alone and in combination with vasculoprotective factor, the ANGPT1, 
by aerosol technique in a rabbit model of asthma related-airway inflammation. Given the 
anti-inflammatory, anti-permeability, and endothelial-protective characteristics of ANGPT1, 
we hypothesise that, combining MSCs with ANGPT1 offers promise in the treatment of 
airway inflammation. Transfection of hAD-MSCs with ANGPT1 was performed using 
microporation technique. For in vivo study, the rabbit were sensitised with combination of 
ovalbumin (Ova) and alum injection and further challenged with Ova inhalation to induce 
asthma-related airway inflammation. The MSCs and MSC-pANGPT1 were aerosolised 
directly into the airway using the MicroSprayer® Aerosolizer 48 h after injury. 
Histopathological assessments of the airway inflammation along with local inflammatory 
responses were quantitatively measured at three days after cell delivery. To investigate the 
functional effect of MSCs on airway regeneration and repair, an indirect in vitro co-culture 
model of injured airway epithelium explant with MSCs was developed. Liquid 
chromatography-tandem mass spectrometry (LC-MS/MS) analysis was performed to 
determine the factors secreted by MSCs and their involvement in epithelium regeneration 
and repair was evaluated by histopathological assessment. The present study provides 
evidence that the microporation technique is superior to the others in terms of its ability to 
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transfect hAD-MSCs without affecting the proliferation and differentiation capabilities of 
MSCs. Administration of aerosolised MSCs and MSC-pANGPT1 markedly reduced 
inflammation of the airways, as reflected by decreased of airway wall thickening and 
infiltration of granulocytes at the peribronchiale and perivascular regions. They also 
alleviated the number of airway inflammatory cells in the bronchoalveolar lavage (BAL) 
fluid and goblet cell hyperplasia. Administration of aerosolised MSC-pANGPT1 provided an 
additional effect merely in reducing the expression levels of various pro-inflammatory genes 
to the baseline values. In the co-culture assay, histological analysis provided strong evidence 
of the stimulatory behaviours of MSCs to enhance the migratory, proliferative and 
differentiation abilities of airway epithelial cells (AECs) in repairing the injured airway 
epithelium. Compounds secreted by MSCs also markedly initiated the epithelial-to-
mesenchymal transition (EMT) process during early wound repair. The identification of 54 
of MSC-secreted proteins of which approximately 43 of them were found to be involved in 
airway epithelial cell migration, proliferation, differentiation and initiation of EMT process. 
This occurrence further supports the evidence of MSCs stimulatory ability in accelerating 
airway regeneration and repair. This study provides cellular and molecular insights of MSC-
based therapy to form a basis evidence for future treatment to treat lung injuries.  
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CHAPTER 1  
GENERAL INTRODUCTION 
 
1.1 Anatomy of the respiratory airway 
1.1.1 The branching of respiratory airway 
The lung is made up of complex branches of airway tubes linked to a trachea that 
carry air to and from the alveoli, where gas exchange occurs (Hogan et al., 2014). Lung can 
be divided into two general parts which are the conducting and the respiratory parts (Figure 
1.1). In human, the conducting airway from the trachea to bronchioles is a set of tubular 
structure lined by pseudostratified epithelium, comprises of three main cell types: ciliated 
cells, non-ciliated secretory cells, and basal cells. This cellular composition of the 
conducting airway differs along its proximal-distal axis (Figure 1.2) (Rock, Randell and 
Hogan, 2010). This respiratory tract decreases in luminal diameter as the airway tree 
branching down from proximal to distal. The respiratory part encompasses respiratory 
bronchioles that branch into alveolar ducts and alveolar sacs at the terminal (Donne, Lechner 
and Rock, 2015).  
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Figure 1.1 Schematic of the human respiratory system. Respiratory airway is divided into 
two general zones, the conducting zones and the respiratory zone. Adapted from 
(Kleinstreuer, Zhang and Donohue, 2008). 
 
1.1.2 Respiratory airway structure and cellular composition 
1.1.2(a) Proximal airway 
The proximal part of conducting airway termed as tracheobronchial tree (airway 
structure involving the trachea and bronchi) is made up of C-shaped rings of hyaline 
cartilage composed of chondrocytes. These cartilaginous rings are to support trachea rigidity 
and provide protection to the trachea from collapsing owing to extreme condition including 
cough and forced expiration (Fernandez, Norwood and Berne, 2008). Tracheobronchial 
surface is lined by a pseudostratified mucociliary epithelium that primarily includes 
multiciliated, secretory/goblet, basal cells and neuroendocrine cells (Figure 1.2). Ciliated 
cells are the major cellular constituents lining the tracheobronchial surface, followed by 
basal and fewer number of secretory/goblet cells (Plopper et al., 1983). Ciliated cells are 
terminally differentiated cell population that are marked by the expression of cytokeratin 8 
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(CK8) and 18 (CK18) (Rawlins and Hogan, 2008; Cole et al., 2010). Basal cells lined the 
pseudostratified epithelium, tightly anchored the epithelium to the basement membrane via 
hemidesmosomes and other adhesion molecules. They constitute approximately`6 – 30% of 
the total epithelial cells in human conducting airway, characterised by the expression of 
transcription factor-63 (p63), CK5, CK14, and Nerve Growth Factor Receptor (NGFR) 
(Nakajima et al., 1998; Rock et al., 2009; Kotton and Morrisey, 2014). However, the 
proportion of basal cells differs along the proximal-distal axis. In human airway, basal cells 
are abundant in the trachea and in the first six generations of the respiratory tract. 
Accumulating evidences suggest that basal cells are stem cells that are capable to self-renew 
and differentiate into ciliated and secretory/Club cells during homeostasis or following injury 
(Rock et al., 2009; Crystal, 2014; Weiss et al., 2015). 
The secretory/goblet cells populate the tracheobronchial surfaces, express mucin-5ac 
(Muc5ac) that produces and secretes mucus to create a barrier that inhibit the pathogen from 
penetrating to the conducting airway.  The secretion of mucus by secretory/goblet cell 
together with ciliated cell‟s sweeping motion orchestrate the clearance of mucociliary, the 
process by which inhaled microorganisms and particulates are cleared from the lung. The 
invagination the airway epithelial layer is a layer of sub-mucosa which comprises of sub-
mucosa gland, smooth muscle and blood vessel. These sub-mucosa glands are further 
specialised into mucus cells or serous cells (Puchelle et al., 2006). Goblet cells, Club cells, 
and sub-mucosa gland are identified as mucus-producing cells/structures due to their 
physiological function in producing mucus, which is vital for defensive barrier (Puchelle et 
al., 2006).  
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Figure 1.2 Epithelial cell types in the conducting airways (nasal, trachea, bronchi, and 
bronchiole) and respiratory airways (alveoli). (a) Tracheobronchial of the proximal 
cartilaginous airway are lined with a pseudostratified epithelium that consist of ciliated, 
basal, and secretory/goblet cells, (b) In the more distal airways, the bronchiole region lined 
with a simple cuboidal epithelium consisting of ciliated, basal, and secretory/club cells, and 
(c) gas-exchanging airspace (alveolar region) consisted of two major distinct epithelial cell 
types, ATI and ATII. Adapted from (Wetsel, Wang and Calame, 2011). 
 
1.1.2(b) Distal airway 
As the bronchi branches into bronchioles and to terminal bronchioles in more distal 
airway, the cartilaginous bronchi vanishes and substituted for smooth muscle bordering the 
bronchiole epithelium. This airway area is termed as bronchiolar epithelium. The epithelium 
gradually modifies from pseudostratified to simple cuboidal epithelium and the number of 
ciliated, goblet, and basal cells gradually diminishes distally. In addition, a non-ciliated cell 
named Club cells, marked by the expression of secretoglobins, Scgb1a1 and Scgb3a2 appear 
to be the main cell type in the bronchiolar epithelium (Nettesheim et al., 1990; Reynolds et 
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al., 2002). Under steady state conditions, airway epithelium in proximal and distal regions is 
relatively in quiescent state. The lung maintenance and repair under steady state or in 
response to mild injury is performed by distinct cell population of the airway epithelium 
known as endogenous lung stem/progenitor cells (Kotton and Morrisey, 2014).  
 
1.1.3 Stem cell population in lung 
Lung has an intrinsic capacity to regenerate itself. This endogenous repair 
mechanism have very slow cellular turnover which is less than 1% of epithelial cells that are 
proliferating at any given point in time under normal circumstances (Boers, Ambergen and 
Thunnissen, 1999) . This phenomenon suggests that lung is relatively quiescent under steady 
state conditions. The maintenance of conducting airway epithelium and its repair is 
dependent on the activity of endogenous lung stem cells. These endogenous stem cells reside 
in distinct microenvironment that defined as a „niche‟ along the airway tree from proximal-
to-distal axis (Hegab et al., 2015). These stem cells are critically influenced by extrinsic 
signal within their niche that comprises of extracellular matrix and other cell types including 
epithelial cell, endothelial, mesenchyme and/or hematopoietic cells. The interactions 
between of these cell-cell and cell-extracellular matrix are mediated via signalling 
components such as Wnt and Notch (Flozak et al., 2010; Xing et al., 2012). Both of these 
signalling pathways are known to play key roles in self-renewal and differentiation of the 
stem cells. They are also associated with airway regeneration and repair. Previous studies 
have shown that the activation of canonical Wnt signalling pathway in various lung 
compartments that are undergoing vigorous regrowth and regeneration suggests its important 
involvement in lung regeneration and repair (Hashimoto et al., 2012; Aumiller et al., 2013). 
While Notch signalling has been shown to play a critical role in differentiation of basal cells 
into secretory lineages in respond to sulphur dioxide induced airway epithelial injury (Xing 
et al., 2012).  The interplay between endogenous stem cells and their niches creates dynamic 
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system in regulating long-term maintenance of stem cells. This is achieved by modulating 
self-renewal and/or differentiation capability of stem cell or to cause reversion of 
differentiated cells to stem cell-like functions (Volckaert and De Langhe, 2014a). 
The respiratory airway is equipped with epithelial cell lining to provide structural 
integrity and as the first line of defence mechanism against the external stimuli. Secretory 
products, tight junction between the epithelial as well as movement of cilia are among 
defence mechanisms at the respiratory airway wall (Blanpain, Horsley and Fuchs, 2007; 
Whitsett and Alenghat, 2015). The loss of epithelial cells in response to injury requires the 
presence of stem cells to persistently replenish the epithelium lining. This continuous cell 
replacement process is critical in maintaining the adult tissue homeostasis (Blanpain, 
Horsley and Fuchs, 2007). Initial study by Randell et al (1991)  revealed the potential of 
basal cells in generating a complete pseudostratified epithelium containing basal, ciliated and 
secretory cells when seeded into a denuded trachea grafted. More recently, in vivo genetic 
lineage tracing experiments provided evidence that basal cells have the ability of long-term 
self-renewal and differentiate into multiple airways epithelial cell types such as secretory and 
ciliated cells (Hong et al., 2004; Teixeira et al., 2013). These findings indicated that basal 
cells function as stem cells that are capable of self-renewal and differentiate into epithelial 
lineages to support tissue homeostasis. Apart from basal cells, a subset of epithelial cells that 
make up a population of stem cell of the airway includes Club cells in bronchioles and 
alveolar type II cells (ATII) in the alveoli (Hong et al., 2004; Rock et al., 2009). 
In the proximal airway, previous studies have demonstrated that cytokeratin (CK5) 
and (CK14) positive basal cells have the ability to give rise to ciliated and secretory cells in 
response to chlorine and cystic fibrosis (CF) induced airway injury (Hong et al., 2004; 
Musah, Chen and Hoyle, 2012). In addition, a study Rock et al (2011) showed that basal 
cells proliferate and differentiate into a multipotent p63-CK8+ luminal cells that comprise of 
ciliated and secretory cells following exposure to sulphur dioxide. In the distal bronchioles, 
Club cells are the cell population that functions as stem cells in maintaining the facultative 
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progenitor cell pool and differentiate to ciliated cells. This is because the Club cells are 
abundant in the distal bronchioles than the ciliated cell, whereas basal cell population 
gradually decreases in number distally (Morrisey and Hogan, 2010). According to previous 
work, a rise of proliferative Club cells that express Clara cell secretory protein (CCSP) at the 
terminal bronchiolar airway following naphthalene-induced injury can promote epithelial 
renewal (Reynolds et al., 2000; Hong et al., 2001).  In the alveoli region, ATII cells are 
endogenous stem cell population that have the capability to self-renew and give rise to ATI 
during lung development and repair following injury. Following injury, ATI cells have been 
shown to release an epithelial growth factor (EGF) that activated the ATII to differentiate 
into ATI (Desai, Brownfield and Krasnow, 2014). 
The airway epithelial can undergo phenotypic switches in response to damage tissue. 
In the ablation of airway basal cells, the differentiated airway epithelial cells such as 
secretory cell can revert into functional basal stem cells (Tata et al., 2013). A study by 
Randell and co-workers using denuded rat tracheas indicated that the luminal secretory cells 
have the capability to regenerate the entire epithelium as lectin+ basal cells (Liu, Nettesheim 
and Randell, 1994). Subsequent lineage tracing study by Tata et al (2013) demonstrated that 
differentiated secretory cells expressing secretoglobin 1a1 (Scgb1a1) underwent 
dedifferentiation into Trp63+/CK5+ basal cells in the ablation of CK5-expressing basal cells 
in the mouse trachea in vivo. The generated basal cells persist over the long term and 
indistinguishable from normal CK5+ stem cells which suggests that differentiated cells can 
revert into stem cells and function similarly as their endogenous stem cell counterpart in 
repairing injured epithelial.  
In the context of acute injury, the endogenous stem cell populations of the airway 
epithelium are capable of impacting effective repair (Perl, Riethmacher and Whitsett, 2011). 
However, chronic injury and inflammation due to repeated airway epithelial injury 
frequently associated with aberrant repair. The disruption of reciprocal interaction of 
epithelial stem cell-niche unit and their dysregulation may lead to pathological airway 
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remodelling and serious impairment of lung function as observed in chronic lung diseases 
such as chronic obstructive pulmonary disease (COPD) and chronic asthma (Rock and 
Hogan, 2011; Ganesan and Sajjan, 2013a). 
 
1.2 Lung-related disorder 
Lung diseases have become a major concern in medical care and caused an immense 
global health burden. According to World Health Organization (WHO) statistics, non-
communicable diseases including chronic respiratory diseases were responsible for almost 
68% of all death worldwide in 2012. Chronic respiratory diseases are global health challenge 
that is defined as chronic inflammatory conditions of the conducting airways and lung 
parenchyma (Jeffery, 2001). Two primary debilitating chronic lung diseases are asthma and 
COPD. The current global estimation of people suffering from chronic respiratory disease is 
over 1 billion. Asthma has the highest incidence among the chronic respiratory diseases, with 
about 300 million people were reported to have asthma (Global Initiative for Asthma, 2018), 
while 210 million people suffer from COPD and patients suffer from these diseases can be 
fatal if left untreated. These diseases are predicted to become the third leading cause of death 
in the world by 2030 (World Health Organization, 2008). This imminent fact may contribute 
to the global burden on healthcare system, economy, and capital human resources, hence the 
development of better treatment aimed to prevent and cure chronic respiratory diseases are 
urgently needed.  
 
1.2.1 COPD  
COPD is a complex disorder characterised by progressive irreversible airflow 
obstruction that interferes with normal breathing, persistent systemic and airway 
inflammation. Patients with COPD usually come together with various co-morbid diseases 
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such as cardiovascular (Crisafulli et al., 2008; Decramer, Janssens and Miravitlles, 2012). 
The predominant cause of this disease is cigarette smoke, however other factors including air 
pollution and occupational exposures to dusts and fumes  (Harber et al., 2007; Thorley and 
Tetley, 2007; Johannessen et al., 2012; Omland et al., 2014; To et al., 2016). COPD 
primarily manifests by emphysema and chronic bronchitis - they frequently coexist. Other 
clinical manifestations of COPD are mucus hypersecretion, systemic inflammation and, 
acute exacerbation that lead to decrease in lung function and breathe shortness (Hogg, 2004; 
Wright, Cosio and Churg, 2008; Baraldo, Turato and Saetta, 2012; Tuder and Petrache, 
2012). Emphysema is a condition of an abnormal permanent enlargement of alveolar spaces 
due to the destruction of alveolar septa. The damage of the alveolar walls reduces the overall 
elasticity of the lung which leads to the collapse of the bronchioles obstructing airflow out of 
the alveoli (Shaker et al., 2009; De Torres et al., 2011). This incidence causes difficulties in 
breathing due to obstructed airflow. 
 
1.2.1(a) Chronic bronchitis 
Chronic bronchitis (CB) is a common but variable phenomenon in COPD defined as 
the incidence of a chronic, productive cough and production of sputum no less than 3 
consecutive months in 2 consecutive years (Kim and Criner, 2013). The clinical phenotype 
of CB in COPD is associated with an increased exacerbation rate, accelerated decline in lung 
function, increased risk of respiratory infections, worse health-related quality of life 
(HRQoL) and increased risk of mortality (Vestbo et al., 1996; Kim et al., 2011; Ramos, 
Krahnke and Kim, 2014). Accumulating data suggest that the secretion from goblet cells and 
mucous gland variably described as mucus overproduction and hypersecretion is a 
pathologic foundation for CB (Kim and Criner, 2013; Kim et al., 2015). Mucus 
overproduction and hypersecretion by goblet cells lead to airflow obstruction by several 
mechanisms including luminal occlusion of small airways, airway narrowing caused by 
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thickening of epithelial layer, epithelial remodelling, inflammation and swelling of the lining 
of the airways (Hogg et al., 2004; James and Wenzel, 2007). The inflammation starts to 
stimulate production of mucous and in longer time it may change to sputum, which can 
cause further obstruction of the airways. Obstruction of the airways, especially with mucus, 
increases the possibility of bacterial lung infections (Garcia-Bellmunt et al., 2013). Previous 
study demonstrated that chronic mucus hypersecretion in hospitalised COPD patients 
increased mortality risk associated with pulmonary infection (Prescott, Lange and Vestbo, 
1995).  
 
1.2.1(b) Bronchiectasis 
Bronchiectasis is another abnormality that can be found in patients with COPD 
(Martínez-García et al., 2011). Both bronchiectasis and COPD share numerous 
characteristics including fixed airway obstruction, chronic cough and production of sputum. 
Accumulating data suggest that COPD coexisting with bronchiectasis indicated by the 
discovery of bronchiectasis on high-resolution CT scans (HRCT) in patient with COPD is 
associated with poorer outcome. Coexisting of COPD and bronchiectasis resulting in 
advance lung dysfunction, frequent exacerbation and colonisation of bacteria (Martínez-
García et al., 2013). In bronchiectasis, serious and recurrent infections of the lung as well as 
abnormal development of the lung results in permanent damage to the airways (McShane et 
al., 2013). The damaged airways become enlarged tubes or, in more severe cases, large sacs. 
These segments of lung can impair clearance of secretions. The damaged, mucus-filled 
airways often become infected, resulting in further inflammation and damage to the airways 
(Boyton, 2012). 
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1.2.2 Asthma  
Asthma is a complex, reversible chronic airway inflammatory disorder orchestrated by 
complex interactions between genetic factors and environmental agents likes aeroallergens 
and respiratory viruses (Gregory and Lloyd, 2011; Reddel et al., 2015). Asthma affects 
approximately 300 million people of all age groups worldwide and its prevalence is 
increasing (Global Initiative for Asthma, 2018). Of these, 10 – 15% were reported to have 
severe asthma, which is refractory to commonly drug therapies (WHO, 2007; Croisant, 
2014). However the cost of health care for severe asthma is estimated to account for more 
than 60% of the costs related to asthma treatment and management, which are mainly for 
medications (Sadatsafavi et al., 2010). In Malaysia, approximately 1.6 million to 2 million 
people were reported to have asthma and the number is still increasing, especially among 
children (Ngui et al., 2011; Roslan et al., 2011). The majority of asthmatic patients 
experience recurring episodes of nocturnal coughing, breathlessness, wheezing and chest 
tightness,  together with variable expiratory airflow limitation due to the inflammation and 
constriction of muscle surrounding the airway (Lambrecht and Hammad, 2012). Besides, a 
small proportion of asthmatic patients suffer from persistent symptoms and a progressive 
decline in lung function (Lee et al., 2011a). The factors that lead to declining lung function 
remain uncertain, but chronic progressive airway wall remodelling may be at work (Lee et 
al., 2011). Asthma remains a health threat and has become a major cause of morbidity and 
mortality worldwide as it also associated with exacerbations whereby asthmatic patients have 
worsening of their symptoms often precipitated by infection. These exacerbations magnify 
the morbidity and considerably contribute to the mortality rate of asthma (George and 
Brightling, 2016).  
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1.2.2(a) Pathophysiology of asthma 
 Asthma is a phenotypically heterogeneous chronic airway disease characterised by 
airway inflammation, airway-wall remodelling, airway smooth muscle contraction and 
hyperreactivity as well as increased mucus production. Airway inflammation is hallmark in 
mild-to-moderate asthma which is common and known as type 2 inflammation. This type 2 
inflammation is driven by inflammatory cytokines (interleukin-4 (IL-4), interleukin-5 (IL-5), 
and interleukin-13 (IL-13) secreted by type 2 helper T (Th2) cells (Figure 1.3) and generally 
promptly resolves after treatment with glucocorticoid (Israel and Reddel, 2017). These 
cytokines are also produced by innate lymphoid cells in response to infectious agents. Since 
the production of eosinophils is promoted by IL-4 and IL-5, this inflammation is often 
characterised by eosinophils (Nakagome and Nagata, 2011). 
 
Figure 1.3 Overview of asthma pathophysiology as illustrated by the interaction 
between different inflammatory cells and the external environment including allergens. 
Key players in this mechanism include the T helper type 2 (Th2) cells which secrete 
cytokines including IL-4, IL-5 and IL-13, that activate inflammatory cells such as 
eosinophils and mast cells. Ultimately, airway smooth muscle cells are activated and airway 
epithelial cells over-secrete mucus (Jameson and Weetamen, 2012) 
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1.2.2(b) Mild-to-moderate asthma 
  Th2-mediated eosinophilic airway inflammation is associated with varying degree of 
asthma severity, ranging from mild-to-moderate to severe uncontrolled disease (Pelaia et al., 
2015). Analysis of sputum or bronchoscopic sampling suggested that eosinophilic airway 
inflammation is believed to play essential roles in the pathogenesis of asthma via the 
secretion of various inflammatory mediators together with cytotoxic eosinophils-derived 
granule proteins and lipid mediators in the airway (Amin, Janson and Bystrom, 2016). These 
mediators promote persistent inflammation that ultimately leading to the asthmatic 
exacerbations and declined lung functions which is generally observed in biopsies of 
asthmatic patients lung (Young et al., 1986; Trautmann et al., 2002; Acharya and Ackerman, 
2014). Increasing evidences established that eosinophils essentially contribute to airway 
remodelling in asthma (Nakagome and Nagata, 2011). A study by Halwani et al (2013) 
reported that eosinophils promote airway remodelling during asthma by triggering airway 
smooth muscle (ASM) cell proliferation and thus increasing ASM mass. Another study by 
Humbles (2004) reported that allergen challenge of mice with selective ablation of the 
eosinophil lineage showed that eosinophils were required for an increment in ASM cells and 
collagen deposition  suggesting an important role of eosinophils in the development of 
airway remodelling. Similar findings were also reported by Flood-Page et al (2003) and Lee 
et al (2004). 
 
1.2.2(c) Severe asthma 
Nonetheless, in the context of severe asthma, there are compelling evidences which 
suggest that a neutrophilic inflammation, orchestrated by type 1 helper T (Th1) and 
especially type 17 helper T (Th17) lymphocytes is more profound in patients with severe 
asthma (Baines et al., 2011; Wood et al., 2012; Simpson et al., 2014). Wenzel and co-
workers reported that there is a high neutrophils number in the airway lavage of patients with 
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severe asthma compared to patients with mild and moderate asthma (Wenzel et al., 1997). It 
is thought to be involved in the progression of more severe irreversible airway obstruction 
leading to sudden death (Shaw et al., 2007). This statement was supported by the evidence of 
an excess neutrophils in airway secretions and sub-mucous glands in biopsy sample from 
patients with fatal asthma (Carroll, 2002). There were also evidences stated that mast cells 
have been linked to the  pathophysiology of asthma and often associated with more severe 
asthmatic phenotypes (Galli and Tsai, 2012; Andersson et al., 2016). Abundant of mast cells 
are found to be localised within the bronchial smooth muscle bundles in severe asthma and 
trigger airway remodelling by secreting inflammatory mediators likes amphiregulin (Lei et 
al., 2013; Andersson et al., 2016). Therefore, if left untreated, asthma can lead to the airway 
irreversibility such as airway wall remodelling which is another key feature of asthmatic 
airways that has been shown to correlate with the disease severity.  
 
1.2.2(d) Airway remodelling 
In severe asthma, the term "airway remodelling" denotes the structural alteration that 
occurs in conjunction with, or as a consequence of, chronic inflammation, contributing to 
airway obstruction. Airway remodelling refers to a compilation of structural modification 
characterised by epithelial damage and hyperplasia, deposition of extracellular matrix (ECM) 
factors below the basement membrane (making the airways less compliant), proliferation of 
airway smooth muscle, angiogenesis and excess mucus production contribute to the 
thickening of the airway wall (Figure 1.4) (Evans et al., 2009; Halwani, Al-Muhsen and 
Hamid, 2010; Lambrecht and Hammad, 2012; Martin and Verma, 2012). Jeffery et al (2001) 
described that the asthmatic airway walls are generally thickened between 50 and 300% 
relative to the normal airway walls due to airway remodelling that is attributed to alteration 
of airway epithelium, basement membrane and sub-mucosa. This phenomenon leads to 
luminal narrowing. Furthermore, the epithelium layer of the nasal and lower airways in the 
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asthmatic individuals appears to be more fragile and easily detach from the basement 
membrane. The consequence of these structural changes may cause partially reversible 
airway narrowing in mild asthma but mostly irreversible in chronic severe asthma airway 
together with airway hyperresponsiveness (AHR), mucus hypersecretion and airway oedema 
leading to a progressive decline in pulmonary function. There is growing support for a role 
of aberrant airway epithelial repair processes in response to persistent inflammatory response 
implicated in the development of pathological airways remodelling (Bai, 2010; Ganesan and 
Sajjan, 2013a). In addition, the accumulation of fibroblasts which leads to ECM deposition is 
also a causal factor (Pain et al., 2014).  Hence, airway remodelling in asthma may results to 
asthma exacerbations and even death from airway obstruction caused by contraction of 
smooth muscle, airway oedema, and mucus plugging. It is unclear that current drug therapies 
such as inhaled corticosteroid (ICS), long-acting B-adrenoreceptor agonist and tiotropium 
that are used for the treatment of inflammation are adequate for airway remodelling 
treatment as well. These drugs are effective in alleviating inflammation and preventing 
airway remodelling in animal models (Alrifai et al., 2014). However, there is no currently 
available therapy targeting airway remodelling in human, even though reversibility of airway 
remodelling is suggested by studies in animal models of disease. 
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Figure 1.4 A significant structural remodelling of airway walls in asthmatic patients 
relative to normal individual. Histological section of a medium sized airway from a non-
asthmatic patient and a patient with severe asthma stained with Movat‟s pentachrome stain. 
In asthma the epithelium (Ep) displays mucus hyperplasia and hypersecretion (blue), and a 
significant thickening of the basement membrane (Bm). Smooth muscle (Sm) volume is also 
increased in asthma. Bv=blood vessel. Adapted from (Wadsworth, Yang and Dorscheid, 
2013). 
 
1.2.2(e) Vascular permeability in asthma 
Vascular component of airway remodelling contributes to the alteration of the 
airway wall in asthma which may be associated with disease progression. The vessels 
present in the sub-mucosa region of asthmatics are more permeable (Nagy et al., 2008). 
Some reports confirmed the relevant occurrence of this phenomenon in airways of asthmatic 
patients (Kanazawa, Hirata and Yoshikawa, 2002; Asai et al., 2003; Kanazawa, Nomura and 
Yoshikawa, 2004). In these studies, the permeability of microvascular was examined using 
the airway vascular permeability index. This index is measured by the level of albumin in 
induced sputum/albumin in serum (Kanazawa, Hirata and Yoshikawa, 2002), or as 
fibronectin concentrations (Meerschaert et al., 1999) or alpha 2-macroglobulin (Svensson et 
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al., 1995) levels in the BAL fluid (James, Paré and Hogg, 1989).  Increased microvascular 
permeability is a criterion for airway inflammation, since the extravasation of inflammatory 
cells to the airway requires vascular leakage and leukocytes transmigration through the 
endothelium. This plasma leakage can also lead to mucosal oedema and bronchial wall 
thickening, thereby reducing the airway lumen, which in turn causes airflow limitation and 
may contribute to AHR. Plasma extravasations can compromise epithelial integrity and 
contribute to formation of luminal mucus plugs (James, Paré and Hogg, 1989). These 
phenomena are common features during vascular remodelling in bronchial asthma (Zanini et 
al., 2010).  McDonald (1990) described a role of intercellular gaps between endothelial cells 
(ECs) of post capillary venules in microvascular permeability using animal models. Increase 
in vascular permeability results from the gaps in the endothelium that permit the 
extravasation of plasma proteins into the mucosal connective tissue and even into the airway 
lumen.  
Besides, the immature and unstable nature of new capillaries during the chronic 
inflammation process lead to increased permeability of the microvascular (Otani et al., 
2004). The increased microvascular permeability is attributable to the secretion of 
inflammatory mediators, growth factors, neuropeptides, cytokines, eosinophil granule 
proteins, and proteases. A pro-leakage factor, vascular endothelial growth factor (VEGF) 
plays critical role in vascular permeability of the airway. The expression of VEGF has been 
shown to be increased in asthma and correlated with alteration in cell-cell junction, an 
increase in vessel permeability and leakage of plasma constituents into the airway 
(Kanazawa, Hirata and Yoshikawa, 2002; Kanazawa, Nomura and Yoshikawa, 2004). The 
anti-permeability factors such as Angiopoietin-1 (ANGPT1) on the other hand, function to 
stabilise the nascent vessels, making them resistant to leakage by increasing the vascular 
integrity. For example, mice transgenic for ANGPT1 have leakage-resistant blood vessels 
(Thurston et al., 1999). The development of new therapy using this ANGPT1 might be 
beneficial in maintaining the integrity of ECs and thus reduce the airway inflammation. 
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1.2.2(f) Treatment options in managing asthma 
Current drug therapy for asthma has been successful at managing asthmatic 
symptoms as up to 75% of individuals suffering from asthma can attain sufficient asthma 
control on inhaled corticosteroids (ICS with and without long-acting β2-agonists (LABA) 
(Bateman et al., 2004; Royce and Tang, 2009). Development of asthma medication is to 
prevent and control asthma symptoms, reduce the frequency and severity of asthma 
exacerbation and reverse airflow obstructions (Dahl, 2006). Asthma medication can be 
classified as either bronchodilator for airway SM relaxing or as anti-inflammatory drugs to 
suppress airway inflammation. In current practice, asthma medications are categorised based 
on their roles in controlling the disease – either as quick relieve or long-term control (Fanta, 
2013). An example of quick relief medication is short-acting β-agonist which is effective in 
quick reversal of airflow obstruction and offers rapid relief of asthmatic attack (Fanta, 2013). 
Salbutamol, levelbuterol and maeprotenerol are drugs that were grouped under such 
medication. Conversely, corticosteroids (or glucocorticosteroids), LABA, leukotriene 
modulators, anti-immunoglobulin-E (IgE) are examples of controller asthma drug (Fanta, 
2013).  The most common used of corticosteroids nowadays is inhaled corticosteroids (ICS). 
ICS is the most effective therapy available nowadays and used as the first-line therapy for 
persistent asthma in adults and children in many countries (Dahl, 2006). Clinical evidences 
suggest that ICS is capable of significantly diminishing airway inflammation and AHR, 
preventing the acute exacerbations, improving lung function and decreasing the symptoms 
severity (Georgitis, 1999). These factors are the key reasons for the widespread use of ICS as 
the frontline in managing asthma which also has been approved by both national and 
international guidelines (Dahl, 2006). 
 Apart from the positive results of ICS, there were also debates concerning the role of 
ICS in restoring the airway structure (Georgitis, 1999; Dahl, 2006). As mentioned earlier, 
asthma is characterised by changes in the epithelial structure which include epithelial 
damage. Several in vitro studies demonstrated that corticosteroids could increase the 
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apoptosis of epithelial cells which is in the case of asthma, this could further leads to chronic 
epithelial damage (Mauad, Bel and Sterk, 2007). In contrast, in a retrospective biopsy study, 
prolong treatment of ICS (10 years) did augment the inflammation and moderately improved 
the epithelial damage (Lundgren et al., 1988). The chemical constituent of ICS may also 
cause adverse effects to the human beings. Although most of the currently available ICS 
have been designed to undergo first-pass metabolism inactivation in the liver subsequent to 
absorption from the gastrointestinal tract before reaching the systemic circulation (Wood and 
Barnes, 1995; Fanta, 2013). Yet, it is important to note that prolonged usage of ICS and at 
high doses can cause adverse effects such as accelerated loss of bone mass, osteoporosis, 
oral candidiasis, dysphonia, cataract and many others (Guilbert et al., 2006; Aun et al., 
2009). Furthermore, systemic absorption of ICS may have deleterious effects over long term 
use (Barnes and Adcock, 2003). Despite ICS is highly effective at controlling asthmatic 
symptoms, at practical level, only 30-40% of individuals with asthma attained adequate 
asthma control with ICS with or without LABA (Reddel, 2012). This suboptimal asthma 
control occurred due to various causes and poor adherence with asthma medications is the 
main cause. This factor can cause persistent asthma symptoms that finally may contribute to 
severe asthma (Bardin et al., 2017). 
There is a significant unmet need for the therapy of severe asthma that affect 
approximately 20% of patients with asthma (Hetherington and Heaney, 2015). The major 
obstacle in this small proportion of patients with severe asthma is that they are resistance to 
therapeutic effect of corticosteroids. Current treatment guidelines advise high-dose ICS 
and/or systemic corticosteroid to avoid severe asthma from becoming „uncontrolled‟, 
however it is now accepted that many aspects of asthma are not corticosteroid responsive 
(Chung, 2015). Hence this therapy may not provide clinical benefit in many patients 
(Hetherington and Heaney, 2015). These problems highlight the need to find alternative 
therapy with fewer side effects such as stem cell-based therapy. 
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1.2.2 (g) Asthma model 
Asthma led to thousands of death annually worldwide (Global Initiative for Asthma, 
2018). Therefore, the development of prevention strategies and new therapy methods is a 
must. Animal has been used in drug discovery study to eliminate the needs on manipulating 
human in research (Van der Velden and Snibson, 2011). In remodelling of human respiratory 
system, the reason in using the animals as a model study is that the animals provide 
experimental settings that allow us to understand the interaction between immune system 
with functioning respiratory systems. In order to better mimic the pathophysiology of a 
human lung disease, animal with large size is the suitable to be used since the complexity of 
the lung structure is more similar and identical to human as compared with small size 
animals (Van der Velden and Snibson, 2011). There are many asthma models described in 
the literature, using various methods to better mimic human asthma. They represent a 
scenario to understand disease pathophysiology and for discovery of potential novel 
treatments and to improve the existing medications. An ideal animal model of asthma must 
have the capability to reproduce both anatomical and physiology features mimic to human 
asthma. This includes IgE-mediated sensitivity to antigens, increase airway resistance, acute 
bronchoconstriction, chronic airway inflammation, eosinophils influx, mucus hypersecretion, 
production of Th2 cytokines, airway-wall remodelling and many others. In developing 
animal model of asthma-related airway inflammation, rabbit is a suitable candidate due to its 
ability to develop disease from the point being sensitised with allergen for a prolonged 
period (Matute-Bello, Frevert and Martin, 2008). Rabbits also shared similarities with human 
airways and it is phylogenetically closer to human than any other rodents (N A 
Kamaruzaman et al., 2013). Both rabbit and human have abundant sub-mucosa glands and 
mucus secreting goblet cells in the upper airways in contrast to mice(Koehler et al., 2005). 
Previous study had used rabbits as a model to investigate the efficacy of lung reduction 
surgery in the treatment of emphysema and COPD (Keir and Page, 2008a). The treatment 
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was found successful and being use at clinical setting in recent years. Sharing similarities 
with human lungs make rabbits a useful tool as model to study asthma. 
The nature of the inflammatory model may be influenced by the choice of the allergen, the 
sensitisation and challenge protocol and the choice of animal strain (Zosky and Sly, 2007).   
To mimic the pathogenesis of human asthma, protocols for development of animal models 
must include a sensitisation and a challenge phase. Generally, repeated doses of systemic 
allergen administration together with adjuvants, such as aluminium hydroxide are used to 
increase immune response. Allergens that have been used in animal models including 
ovalbumin (Ova), house dust mite (HDM), fungi (Aspergillus fumigatus, Alternaria 
alternata), cockroach extracts, Ascaris antigens, cotton dust, ragweed and latex (Hevea 
brasiliensis) (Zosky and Sly, 2007). The choice of allergen is depending on the condition to 
be replicated and it can be used separately or in combination. Classically, Ova has been 
widely used to induce an allergic reaction in animals, and whilst it is possible to reproduce 
many of the features of the asthmatic lung, i.e. specific immunoglobulin (Ig)E levels, T-
helper cell (Th)2-associated eosinophilic inflammation, early and late asthmatic responses 
(EAR and LAR, respectively), and AHR and airway remodelling (Fuchs and Braun, 2008). 
Ova, however, is seldom implicated human asthma, and other groups have used alternative 
allergens that may have greater clinical relevance, such as HDM and cockroach extract (Aun 
et al., 2017). HDM is an aeroallergen that has been successfully used to induce asthma in 
animal models. Three characteristics of this allergen that make it suitable are they have an 
intrinsic enzymatic activity, immunogenicity and direct activation through the Dectin-2 
receptor of innate immune cells that promote allergic inflammation are the three 
characteristics that make HDM suitable to be used as allergen to induce asthma (Kim et al., 
2006). A large proportion of human asthmatic patients have elevated levels of HDM specific 
IgE and, after challenge with HDM, exhibit EAR, LAR and increases in airway 
inflammation (Aun et al., 2017).Though, HDM is quite dangerous as exposure to HDM by 
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any genetic susceptible individuals can cause symptoms from as mild as atopic dermatitis to 
bronchial asthma.  
 
1.3 Angiopoietin 1 and 2 
Angiopoietins are major vascular regulators that play critical roles in regulating 
vascular homeostasis via vascular endothelial tyrosine kinase receptor, Tie2 signalling that 
highly expressed on ECs under normal or pathologic conditions (Eklund and Olsen, 2006; 
M. Kim et al., 2016). Tie2 is primarily involved in angiogenesis, in conjunction with VEGF. 
In addition to angiogenesis, Tie2 receptor is also essential in vascular integrity maintenance 
in the embryo and in the adults. Both Angiopoietin-1 (ANGPT1) and angiopoietin-2 
(ANGPT2) are ligands that share similar structures and compete for Tie-2 receptor with 
equal affinity but leading to opposing effects (Fukuhara et al., 2008).  
ANGPT1 belongs to the endothelial growth factors that are predominantly expressed 
by pericytes and vascular smooth muscle cells located within the vascular basement 
membrane (van Meurs et al., 2009). ANGPT1 plays critical role in embryonic vascular 
development since deletion of either ANGPT1 or Tie2 has been associated with embryonic 
fatality (Suri et al., 1996). While in the adult‟s vasculature, ANGPT1 is essential for the 
maintenance of microvascular endothelium integrity. ANGPT1 triggers Tie2 
phosphorylation signalling in promoting normal quiescent vascular phenotype of vascular 
ECs, reducing endothelial permeability and alleviating vascular inflammation (Gamble et al., 
2000; Fukuhara et al., 2010). ANGPT1 is also involved in promoting ECs survival, 
stabilising the growing vessels as well as attenuating the activation of vascular endothelial 
barrier to prevent capillary leakage and leukocyte transmigration into the tissues by altering 
the ECs adhesion molecules and cell junction (Augustin et al., 2009; Moss, 2013). ANGPT2 
on the other hand generally has an opposing action. Despite binding of ANGPT1 to Tie2 
primarily activates the receptor, the antagonist ANGPT2, may counteract these functions by 
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binding to Tie2 without inducing phosphorylation, disrupts the connections between the 
endothelium and perivascular cells and thus reduce vascular integrity, provoke inflammation, 
and promote vascular leakage (Fiedler and Augustin, 2006; Saharinen et al., 2008; Hakanpaa 
et al., 2015). ANGPT2 functions as a context-dependent Tie2 antagonist, generally incapable 
to activate Tie2 except presented at high concentration or in prolonged time under in vitro 
settings. Tabruyn et al (2010) suggested that ANGPT2 competitively suppressed the 
ANGPT1 action by increase binding to Tie2 resulting in vascular remodelling and 
inflammation. Though, there is also conflicting evidence indicating that ANGPT2 may 
possibly induce the activation of Tie2 under certain conditions such as in stressed ECs (Daly 
et al., 2006; Koh, 2013). 
There are accumulating studies that are investigating the role of ANGPT1/Tie2 
system in the pathophysiology of respiratory diseases. This is primarily due to the anti-
inflammatory, anti-permeability, and endothelial-protective effects of ANGPT1. Impaired 
ANGPT1/Tie2 system allows migration and infiltration of inflammatory cells from 
circulation into the airways tissue that will cause inflammation (Makinde and Agrawal, 
2008). High circulating ANGPT2 level was observed in exacerbated asthma patients 
indicating that the serum level of pro-angiogenic factors may correlate on-going asthmatic 
exacerbated state and serve as a potential biomarker of the disease severity. In contrast, 
circulating levels of ANGPT1 in plasma of asthmatic patients were found to be reduced (Lee 
et al., 2016). ANGPT1 has been shown to supress leukocytes adhesion to ECs by reducing 
the expression of VEGF-induced adhesion molecules including intercellular adhesion 
molecule-1 (ICAM-1), vascular cell adhesion molecule-1 (VCAM-1), and E-selectin (Kim et 
al., 2001). The binding of leukocytes to ECs via these molecules is an early and important 
step towards inflammation (Ismail et al., 2012). Simoes et al (2008) further demonstrated 
that administration of ANGPT1 via intranasal route reduced airway inflammation and 
hyperreactivity in Ova-induced asthma model. In a separate study, Xu et al (2008) showed 
that the expression of ANGPT1 reduced the permeability of ECs and inflammation in 
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pathogenesis of acute respiratory distress syndrome (ARDS). In term of vascular 
permeability, treatment with ANGPT1 has been shown to support ECs junctions tightening 
by increasing the localisation of platelet endothelial cell adhesion molecule-1 (PECAM-1) to 
these junctions and attenuate leukocyte transmigration (Gamble et al., 2000). In a separate 
study, Kanazawa et al (2007) described an inverse correlation between ANGPT1 level and 
vascular permeability index in asthmatics patients. They found that the vascular permeability 
was associated with increased VEGF level (pro-leakage) and decreased ANGPT1 level (anti-
leakage).  Mei et al (2007) showed that pre-treatment with ANGPT1 in endotoxin-exposed 
mice suppressed the vascular leakage leading to decrease in granulocytes influx and pro-
inflammatory mediators in animal model of lipopolysaccharide (LPS)-induced acute lung 
injury (ALI). This result provides further evidence suggesting the protective effect of 
ANGPT1 in protecting the adult vasculature against plasma leakage. Agonist activity of 
ANGPT1 on the Tie2 receptor has vast potential for being a candidate of gene therapy in 
treating airway inflammation and previously been studied in the ALI by other groups (Mei et 
al., 2007; Xu et al., 2008). In general, most findings suggest that ANGPT1 provides 
beneficial effect in the treatment of lung diseases. 
 
1.4 Cell-based therapy using MSCs 
Cell-based therapy as a treatment for lung diseases is a rapidly growing field in 
regenerative medicine. Several preclinical studies reported promising results supporting the 
use of stem cells to treat lung diseases such as pulmonary hypertension (Wang et al., 2007), 
ALI (Wang, Li and Wang, 2013), inflammatory and immune-mediated lung conditions 
(Lama et al., 2007). MSCs represent the most frequently used stem cell type in preclinical 
reports and clinical trials conducted so far. As of April 2016, more than 33 clinical trials 
utilising MSCs to treat lung diseases were registered on the ClinicalTrials website (U.S. 
National Institutes of Health, 2016). 
